# TrialSim Examples

Generate synthetic clinical trial data for testing CDISC-compliant systems, regulatory submission pipelines, and clinical data management tools.

> **TrialSim generates synthetic clinical trial data only.** This is test data for software development, not actual clinical research data. The trial designs, adverse event patterns, and efficacy results are simulated for realistic software testing scenarios.

---

## Quick Start Examples

### Example 1: Generate a Simple Phase III Trial

```
Generate a Phase III oncology trial with 200 subjects
```

This creates:
- Study design with treatment arms
- 200 randomized subjects with demographics
- Baseline characteristics
- Randomization to treatment arms

### Example 2: Generate Adverse Events

```
Generate adverse events for a Phase III immunotherapy trial with 150 subjects
```

This creates:
- Treatment-emergent adverse events (TEAEs)
- Serious adverse events (SAEs)
- Immune-related adverse events (irAEs)
- MedDRA-coded terms with severity grades

### Example 3: Generate Screen Failures

```
Generate screening data with 30% screen failure rate for 100 randomized subjects
```

This creates:
- Complete screening funnel (identified → randomized)
- Screen failure reasons by category
- Eligibility assessments

---

## Phase I: Dose Escalation Examples

### 3+3 Design

```
Generate a Phase I dose escalation study using 3+3 design with 5 dose levels
```

**What you get:**
- 5 dose cohorts (10mg, 20mg, 40mg, 80mg, 160mg)
- 3-6 subjects per cohort based on DLT patterns
- Dose-limiting toxicity events with CTCAE grades
- Escalation decisions documented
- Maximum tolerated dose (MTD) determination

**Example Output Summary:**
```json
{
  "study_design": {
    "design_type": "3+3",
    "dose_levels": [
      {"level": 1, "dose": "10mg", "subjects": 3, "dlts": 0, "decision": "ESCALATE"},
      {"level": 2, "dose": "20mg", "subjects": 3, "dlts": 0, "decision": "ESCALATE"},
      {"level": 3, "dose": "40mg", "subjects": 3, "dlts": 1, "decision": "EXPAND"},
      {"level": 3, "dose": "40mg", "subjects": 6, "dlts": 1, "decision": "ESCALATE"},
      {"level": 4, "dose": "80mg", "subjects": 3, "dlts": 2, "decision": "MTD_EXCEEDED"},
      {"level": 5, "dose": "160mg", "subjects": 0, "dlts": 0, "decision": "NOT_OPENED"}
    ],
    "mtd": "40mg",
    "rp2d": "40mg"
  }
}
```

### BOIN Design

```
Generate a Phase I BOIN design study with target toxicity rate 30%
```

**What you get:**
- Bayesian Optimal Interval (BOIN) escalation rules
- Target DLT rate: 30% (default)
- Lambda_e and Lambda_d boundaries
- Dose allocation based on observed DLT rates
- Isotonic regression for MTD selection

**Example BOIN Boundaries:**
```
Target: 30% | Lambda_e: 0.236 | Lambda_d: 0.359

Decision Rules:
- If observed DLT rate < 0.236 → ESCALATE
- If 0.236 ≤ DLT rate ≤ 0.359 → STAY
- If observed DLT rate > 0.359 → DE-ESCALATE
```

### CRM Design

```
Generate a Phase I CRM study with 6 dose levels, target 25% DLT rate
```

**What you get:**
- Continual Reassessment Method design
- Model-based dose recommendations
- Posterior toxicity probability estimates
- Skeleton (prior toxicity probabilities)
- Coherent dose transitions

### First-in-Human (FIH) SAD/MAD

```
Generate a first-in-human study with SAD and MAD cohorts
```

**What you get:**
- **SAD (Single Ascending Dose):**
  - Healthy volunteer cohorts
  - Sentinel dosing (2 subjects → remaining)
  - 48-hour safety observation periods
  - Intensive PK sampling (pre-dose, 0.5, 1, 2, 4, 8, 12, 24, 48h)
  
- **MAD (Multiple Ascending Dose):**
  - 7-14 day dosing periods
  - Steady-state PK assessment
  - Accumulation ratio calculations
  - Trough level monitoring

**Example SAD Cohort:**
```json
{
  "cohort": "SAD Cohort 1",
  "dose": "10mg",
  "subjects": [
    {"id": "101-001", "sentinel": true, "dose_date": "2024-01-15"},
    {"id": "101-002", "sentinel": true, "dose_date": "2024-01-15"},
    {"id": "101-003", "sentinel": false, "dose_date": "2024-01-17"},
    {"id": "101-004", "sentinel": false, "dose_date": "2024-01-17"},
    {"id": "101-005", "sentinel": false, "dose_date": "2024-01-17"},
    {"id": "101-006", "sentinel": false, "dose_date": "2024-01-17"}
  ],
  "pk_samples": 12,
  "dlts": 0,
  "decision": "ESCALATE"
}
```

### Expansion Cohorts

```
Generate Phase I expansion cohorts for 3 tumor types at RP2D
```

**What you get:**
- Indication-specific cohorts (e.g., NSCLC, melanoma, RCC)
- 20-40 subjects per indication
- Preliminary efficacy signals
- Safety confirmation at RP2D
- Biomarker correlations

---

## Phase II: Proof-of-Concept Examples

### Simon's Two-Stage Design

```
Generate a Phase II Simon's optimal two-stage design, p0=0.10, p1=0.30
```

**What you get:**
- Two-stage enrollment with interim futility
- Stage 1: Enroll n1 subjects, stop if ≤r1 responses
- Stage 2: Continue to N total if >r1 responses
- Optimal design (minimizes expected sample size under H0)

**Example Simon's Design Output:**
```json
{
  "design_type": "Simon's Two-Stage Optimal",
  "null_response_rate": 0.10,
  "alternative_response_rate": 0.30,
  "alpha": 0.05,
  "power": 0.80,
  "stage_1": {
    "n": 10,
    "r": 1,
    "rule": "Stop if ≤1 response in first 10 subjects"
  },
  "stage_2": {
    "N": 29,
    "R": 5,
    "rule": "Reject H0 if ≥6 responses in 29 subjects"
  },
  "expected_sample_size_h0": 17.4,
  "probability_early_termination": 0.736,
  "results": {
    "stage_1_responses": 3,
    "stage_1_decision": "CONTINUE TO STAGE 2",
    "total_responses": 8,
    "total_subjects": 29,
    "response_rate": 0.276,
    "conclusion": "REJECT H0 - PROCEED TO PHASE III"
  }
}
```

### Simon's Minimax Design

```
Generate a Phase II Simon's minimax design for rare tumor, p0=0.05, p1=0.20
```

**What you get:**
- Minimax design (minimizes maximum sample size)
- Higher probability of going to Stage 2
- Lower total N but higher expected N under H0

### Phase II Randomized

```
Generate a randomized Phase II with 2:1 randomization, 80 subjects
```

**What you get:**
- Treatment arm: 53 subjects
- Control arm: 27 subjects
- Response rate comparison
- Preliminary efficacy signals

### MCP-Mod Dose-Ranging

```
Generate a Phase IIb dose-ranging study using MCP-Mod with 5 dose levels
```

**What you get:**
- Multiple Comparison Procedure with Modeling (MCP-Mod)
- Candidate dose-response models (Emax, sigmoid Emax, linear, quadratic, exponential)
- Dose levels: Placebo, 25mg, 50mg, 100mg, 200mg
- Model selection via contrast tests
- Target dose estimation

**Example MCP-Mod Output:**
```json
{
  "design_type": "MCP-Mod",
  "doses": [0, 25, 50, 100, 200],
  "subjects_per_arm": 50,
  "candidate_models": [
    {"model": "Emax", "ed50": 50, "contrast_p": 0.002},
    {"model": "Sigmoid Emax", "ed50": 75, "h": 2, "contrast_p": 0.008},
    {"model": "Linear", "contrast_p": 0.045},
    {"model": "Quadratic", "contrast_p": 0.089},
    {"model": "Exponential", "contrast_p": 0.156}
  ],
  "selected_model": "Emax",
  "target_dose": "100mg",
  "dose_response_curve": {
    "placebo_effect": 2.5,
    "max_effect": 8.2,
    "ed50": 48,
    "ed90": 145
  }
}
```

### Futility Analysis

```
Generate Phase II with interim futility analysis at 50% enrollment
```

**What you get:**
- Interim analysis at n/2 subjects
- Conditional power calculation
- Predictive probability of success
- Go/No-Go decision framework

---

## Phase III: Pivotal Trial Examples

### Superiority Trial

```
Generate a Phase III superiority trial for first-line metastatic NSCLC with 500 subjects
```

**What you get:**
- Large randomized population
- 1:1 randomization to treatment vs SOC
- Primary endpoint: Progression-free survival
- Secondary: Overall survival, ORR, DOR
- Stratification factors (PD-L1 status, smoking history)

### Non-Inferiority Trial

```
Generate a Phase III non-inferiority trial with NI margin of 1.3 HR
```

**What you get:**
- Non-inferiority margin specification
- Sample size for NI conclusion
- One-sided testing at α=0.025
- Sensitivity analyses (per-protocol, as-treated)

### Multi-Regional Trial

```
Generate a global Phase III trial with sites in US, EU, and Asia
```

**What you get:**
- Regional distribution per ICH E17
- Site distribution: 40% US, 35% EU, 25% Asia
- Ethnic sensitivity considerations
- Regional consistency analysis plan

### DSMB Interim Analysis

```
Generate Phase III with 2 interim analyses and O'Brien-Fleming boundaries
```

**What you get:**
- DSMB charter structure
- Interim looks at 33% and 67% information
- O'Brien-Fleming alpha spending
- Efficacy and futility boundaries
- Sample size re-estimation option

---

## Therapeutic Area Examples

### Oncology

```
Generate an oncology trial for Stage IV melanoma with RECIST assessments
```

**What you get:**
- Tumor measurements per RECIST 1.1
- Target lesion selection (≤5 total, ≤2 per organ)
- Best overall response (CR, PR, SD, PD)
- Progression-free survival data
- Overall survival data
- Tumor response kinetics

**Example RECIST Data:**
```json
{
  "subject_id": "CDISC01-101-0001",
  "target_lesions": [
    {"id": "TL01", "location": "Liver", "baseline": 45, "week8": 32, "week16": 28},
    {"id": "TL02", "location": "Lung RLL", "baseline": 23, "week8": 18, "week16": 15}
  ],
  "sum_of_diameters": {
    "baseline": 68,
    "nadir": 43,
    "percent_change_from_baseline": -36.8
  },
  "best_overall_response": "PR",
  "confirmed": true,
  "confirmation_date": "2024-05-15"
}
```

### Cardiovascular

```
Generate a cardiovascular outcomes trial with MACE endpoint
```

**What you get:**
- Major Adverse Cardiovascular Events (MACE)
- Component events (CV death, MI, stroke)
- Time-to-event data
- Heart failure hospitalizations
- Cardiac biomarkers (troponin, BNP)
- Adjudication process

### CNS/Neurology

```
Generate a Phase III Alzheimer's disease trial with cognitive endpoints
```

**What you get:**
- ADAS-Cog scores over time (0-70 scale, higher = worse)
- MMSE assessments (0-30 scale, lower = worse)
- CDR-SB ratings (0-18 scale)
- MRI volumetric data (hippocampal volume)
- Amyloid PET results
- Functional assessments (ADCS-ADL)

### Cell & Gene Therapy

```
Generate a CAR-T cell therapy trial with long-term follow-up
```

**What you get:**
- Single-dose administration (lymphodepletion + infusion)
- Cytokine release syndrome (CRS) events graded per ASTCT
- Neurotoxicity (ICANS) assessments
- Complete response rates by Day 28
- Duration of response
- 5-year follow-up visits (quarterly Year 1, semi-annual Years 2-5)
- B-cell aplasia monitoring
- Immunoglobulin replacement therapy

---

## SDTM Domain Examples

### Demographics (DM)

```
Generate DM domain for 50 subjects in a Phase III diabetes trial
```

**Example Output:**
```csv
STUDYID,DOMAIN,USUBJID,SUBJID,RFSTDTC,RFENDTC,SITEID,AGE,AGEU,SEX,RACE,ETHNIC,ARMCD,ARM,COUNTRY
CDISC01,DM,CDISC01-101-0001,0001,2024-01-15,2024-07-15,101,58,YEARS,M,WHITE,NOT HISPANIC OR LATINO,TRT,Semaglutide 1mg,USA
CDISC01,DM,CDISC01-101-0002,0002,2024-01-18,2024-07-20,101,52,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PBO,Placebo,USA
CDISC01,DM,CDISC01-102-0001,0001,2024-01-20,2024-07-22,102,64,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,TRT,Semaglutide 1mg,USA
```

### Adverse Events (AE)

```
Generate AE domain with immune-related adverse events for checkpoint inhibitor trial
```

**Example Output:**
```csv
STUDYID,DOMAIN,USUBJID,AESEQ,AETERM,AEDECOD,AEBODSYS,AESEV,AETOXGR,AESER,AEREL,AEACN,AEOUT,AESTDTC,AEENDTC
CDISC01,AE,CDISC01-101-0001,1,Diarrhea,Diarrhoea,Gastrointestinal disorders,MODERATE,2,N,PROBABLE,DOSE NOT CHANGED,RECOVERED/RESOLVED,2024-02-15,2024-02-22
CDISC01,AE,CDISC01-101-0001,2,Thyroid function abnormal,Hypothyroidism,Endocrine disorders,MILD,1,N,PROBABLE,DOSE NOT CHANGED,NOT RECOVERED/NOT RESOLVED,2024-03-10,
CDISC01,AE,CDISC01-101-0001,3,Pneumonitis,Pneumonitis,Respiratory disorders,SEVERE,3,Y,DEFINITE,DRUG WITHDRAWN,RECOVERED/RESOLVED WITH SEQUELAE,2024-04-05,2024-05-20
```

### Laboratory (LB)

```
Generate LB domain with hepatic function panel for 20 subjects
```

**Example Output:**
```csv
STUDYID,DOMAIN,USUBJID,LBSEQ,LBTESTCD,LBTEST,LBCAT,LBORRES,LBORRESU,LBSTRESN,LBSTRESU,LBNRIND,VISITNUM,VISIT,LBDTC
CDISC01,LB,CDISC01-101-0001,1,ALT,Alanine Aminotransferase,CHEMISTRY,28,U/L,28,U/L,NORMAL,1,SCREENING,2024-01-10
CDISC01,LB,CDISC01-101-0001,2,AST,Aspartate Aminotransferase,CHEMISTRY,24,U/L,24,U/L,NORMAL,1,SCREENING,2024-01-10
CDISC01,LB,CDISC01-101-0001,3,BILI,Bilirubin,CHEMISTRY,0.8,mg/dL,0.8,mg/dL,NORMAL,1,SCREENING,2024-01-10
CDISC01,LB,CDISC01-101-0001,4,ALT,Alanine Aminotransferase,CHEMISTRY,45,U/L,45,U/L,HIGH,5,WEEK 4,2024-02-12
```

### Vital Signs (VS)

```
Generate VS domain with pre-dose and post-dose vital signs
```

**Example Output:**
```csv
STUDYID,DOMAIN,USUBJID,VSSEQ,VSTESTCD,VSTEST,VSPOS,VSORRES,VSORRESU,VSSTRESN,VSSTRESU,VISITNUM,VISIT,VSTPT,VSTPTNUM,VSDTC
CDISC01,VS,CDISC01-101-0001,1,SYSBP,Systolic Blood Pressure,SITTING,128,mmHg,128,mmHg,2,DAY 1,PRE-DOSE,-15,2024-01-15T08:45
CDISC01,VS,CDISC01-101-0001,2,SYSBP,Systolic Blood Pressure,SITTING,132,mmHg,132,mmHg,2,DAY 1,1 HR POST-DOSE,60,2024-01-15T10:00
CDISC01,VS,CDISC01-101-0001,3,DIABP,Diastolic Blood Pressure,SITTING,82,mmHg,82,mmHg,2,DAY 1,PRE-DOSE,-15,2024-01-15T08:45
```

### Exposure (EX)

```
Generate EX domain for IV infusion regimen
```

**Example Output:**
```csv
STUDYID,DOMAIN,USUBJID,EXSEQ,EXTRT,EXDOSE,EXDOSU,EXDOSFRM,EXDOSFRQ,EXROUTE,EXSTDTC,EXENDTC,EPOCH,EXADJ
CDISC01,EX,CDISC01-101-0001,1,PEMBROLIZUMAB,200,mg,INJECTION,Q3W,INTRAVENOUS,2024-01-15,2024-01-15,TREATMENT,
CDISC01,EX,CDISC01-101-0001,2,PEMBROLIZUMAB,200,mg,INJECTION,Q3W,INTRAVENOUS,2024-02-05,2024-02-05,TREATMENT,
CDISC01,EX,CDISC01-101-0001,3,PEMBROLIZUMAB,200,mg,INJECTION,Q3W,INTRAVENOUS,2024-02-26,2024-02-26,TREATMENT,DOSE DELAY DUE TO AE
```

### Disposition (DS)

```
Generate DS domain with protocol milestones and discontinuations
```

**Example Output:**
```csv
STUDYID,DOMAIN,USUBJID,DSSEQ,DSTERM,DSDECOD,DSCAT,DSSCAT,EPOCH,DSSTDTC
CDISC01,DS,CDISC01-101-0001,1,INFORMED CONSENT OBTAINED,INFORMED CONSENT OBTAINED,PROTOCOL MILESTONE,STUDY PARTICIPATION,SCREENING,2024-01-10
CDISC01,DS,CDISC01-101-0001,2,RANDOMIZED,RANDOMIZED,PROTOCOL MILESTONE,STUDY PARTICIPATION,SCREENING,2024-01-15
CDISC01,DS,CDISC01-101-0001,3,COMPLETED,COMPLETED,DISPOSITION EVENT,STUDY COMPLETION,FOLLOW-UP,2024-07-15
CDISC01,DS,CDISC01-101-0002,1,INFORMED CONSENT OBTAINED,INFORMED CONSENT OBTAINED,PROTOCOL MILESTONE,STUDY PARTICIPATION,SCREENING,2024-01-12
CDISC01,DS,CDISC01-101-0002,2,RANDOMIZED,RANDOMIZED,PROTOCOL MILESTONE,STUDY PARTICIPATION,SCREENING,2024-01-18
CDISC01,DS,CDISC01-101-0002,3,ADVERSE EVENT,ADVERSE EVENT,DISPOSITION EVENT,TREATMENT,TREATMENT,2024-04-20
```

### Medical History (MH)

```
Generate MH domain for oncology trial subjects with comorbidities
```

**Example Output:**
```csv
STUDYID,DOMAIN,USUBJID,MHSEQ,MHTERM,MHDECOD,MHBODSYS,MHCAT,MHPRESP,MHOCCUR,MHSTDTC,MHONGO
CDISC01,MH,CDISC01-101-0001,1,Type 2 diabetes,Type 2 diabetes mellitus,Metabolism and nutrition disorders,GENERAL MEDICAL HISTORY,Y,Y,2018-06-15,Y
CDISC01,MH,CDISC01-101-0001,2,Hypertension,Hypertension,Vascular disorders,GENERAL MEDICAL HISTORY,Y,Y,2015-03-20,Y
CDISC01,MH,CDISC01-101-0001,3,Prior lung cancer surgery,Lobectomy,Surgical and medical procedures,ONCOLOGY HISTORY,N,Y,2022-08-10,N
```

### Concomitant Medications (CM)

```
Generate CM domain with supportive care medications
```

**Example Output:**
```csv
STUDYID,DOMAIN,USUBJID,CMSEQ,CMTRT,CMDECOD,CMCLAS,CMINDC,CMDOSE,CMDOSU,CMDOSFRQ,CMROUTE,CMSTDTC,CMENDTC,CMONGO
CDISC01,CM,CDISC01-101-0001,1,METFORMIN,METFORMIN,BIGUANIDES,Type 2 Diabetes,1000,mg,BID,ORAL,2018-06-20,,Y
CDISC01,CM,CDISC01-101-0001,2,ONDANSETRON,ONDANSETRON,SEROTONIN ANTAGONISTS,Nausea prophylaxis,8,mg,PRN,ORAL,2024-01-15,2024-07-15,N
CDISC01,CM,CDISC01-101-0001,3,DEXAMETHASONE,DEXAMETHASONE,CORTICOSTEROIDS,Infusion reaction prophylaxis,8,mg,ONCE,INTRAVENOUS,2024-01-15,2024-01-15,N
```

---

## ADaM Analysis Dataset Examples

### ADSL (Subject-Level)

```
Generate ADSL for Phase III trial with population flags
```

**Example Output:**
```csv
STUDYID,USUBJID,SITEID,TRT01P,TRT01A,TRTSDT,TRTEDT,AGE,AGEGR1,SEX,RACE,SAFFL,ITTFL,FASFL,EFFFL,EOSSTT,DCSREAS
CDISC01,CDISC01-101-0001,101,Pembrolizumab 200mg,Pembrolizumab 200mg,23391,23543,58,<65,M,WHITE,Y,Y,Y,Y,COMPLETED,
CDISC01,CDISC01-101-0002,101,Placebo,Placebo,23394,23456,52,<65,F,BLACK,Y,Y,Y,Y,DISCONTINUED,ADVERSE EVENT
CDISC01,CDISC01-102-0001,102,Pembrolizumab 200mg,Pembrolizumab 200mg,23396,23548,64,<65,M,ASIAN,Y,Y,Y,Y,COMPLETED,
```

### ADAE (Adverse Event Analysis)

```
Generate ADAE with treatment-emergent flags and first occurrence flags
```

**Example Output:**
```csv
STUDYID,USUBJID,AESEQ,TRTA,AEDECOD,AEBODSYS,AESEV,AESER,ASTDT,AENDT,ASTDY,TRTEMFL,AOCCFL,AOCCPFL,ASER01FL,ADRGIFL
CDISC01,CDISC01-101-0001,1,Pembrolizumab 200mg,Fatigue,General disorders,MILD,N,23408,23415,18,Y,Y,Y,N,Y
CDISC01,CDISC01-101-0001,2,Pembrolizumab 200mg,Diarrhoea,Gastrointestinal disorders,MODERATE,N,23425,23432,35,Y,Y,Y,N,Y
CDISC01,CDISC01-101-0001,3,Pembrolizumab 200mg,Fatigue,General disorders,MODERATE,N,23450,23458,60,Y,N,N,N,Y
```

### ADTTE (Time-to-Event)

```
Generate ADTTE for overall survival and progression-free survival
```

**Example Output:**
```csv
STUDYID,USUBJID,PARAMCD,PARAM,STARTDT,ADT,AVAL,AVALU,CNSR,EVNTDESC,CNSDTDSC,TRTA,ANL01FL
CDISC01,CDISC01-101-0001,OS,Overall Survival,23391,23755,365,DAYS,1,,ALIVE AT DATA CUTOFF,Pembrolizumab 200mg,Y
CDISC01,CDISC01-101-0001,PFS,Progression-Free Survival,23391,23572,182,DAYS,0,DISEASE PROGRESSION,,Pembrolizumab 200mg,Y
CDISC01,CDISC01-101-0002,OS,Overall Survival,23394,23650,257,DAYS,0,DEATH,,Placebo,Y
CDISC01,CDISC01-101-0002,PFS,Progression-Free Survival,23394,23512,119,DAYS,0,DISEASE PROGRESSION,,Placebo,Y
```

### ADLB (Laboratory Analysis)

```
Generate ADLB with baseline and change from baseline for ALT
```

**Example Output:**
```csv
STUDYID,USUBJID,PARAMCD,PARAM,AVISIT,AVISITN,ADT,AVAL,BASE,CHG,PCHG,ANRIND,BNRIND,ABLFL,TRTA
CDISC01,CDISC01-101-0001,ALT,Alanine Aminotransferase (U/L),BASELINE,0,23389,28,28,,,NORMAL,NORMAL,Y,Pembrolizumab 200mg
CDISC01,CDISC01-101-0001,ALT,Alanine Aminotransferase (U/L),WEEK 4,4,23417,45,28,17,60.7,HIGH,NORMAL,,Pembrolizumab 200mg
CDISC01,CDISC01-101-0001,ALT,Alanine Aminotransferase (U/L),WEEK 8,8,23445,38,28,10,35.7,NORMAL,NORMAL,,Pembrolizumab 200mg
```

---

## Safety Data Examples

### Dose-Limiting Toxicities

```
Generate DLTs for Phase I dose escalation
```

**What you get:**
- DLT events by dose level
- CTCAE grade assignments
- DLT evaluation window (typically 21-28 days)
- Attribution to study drug
- Dose cohort decisions

### Serious Adverse Events (SAEs)

```
Generate SAEs for Phase III with seriousness criteria
```

**Example SAE Record:**
```json
{
  "subject_id": "CDISC01-101-0001",
  "ae_term": "Pneumonitis",
  "meddra_pt": "Pneumonitis",
  "meddra_soc": "Respiratory, thoracic and mediastinal disorders",
  "onset_date": "2024-04-05",
  "severity": "SEVERE",
  "ctcae_grade": 3,
  "serious": "Y",
  "seriousness_criteria": {
    "death": "N",
    "life_threatening": "N",
    "hospitalization": "Y",
    "disability": "N",
    "congenital_anomaly": "N",
    "medically_important": "Y"
  },
  "causality": "RELATED",
  "action_taken": "DRUG WITHDRAWN",
  "outcome": "RECOVERED/RESOLVED WITH SEQUELAE",
  "resolution_date": "2024-05-20"
}
```

---

## Enrollment & Recruitment Examples

### Complete Screening Funnel

```
Generate a complete screening funnel for 200 randomized subjects
```

**Output includes:**
```json
{
  "funnel": {
    "identified": 450,
    "pre_screened": 380,
    "consented": 320,
    "screened": 310,
    "screen_failed": 95,
    "eligible": 215,
    "randomized": 200
  },
  "conversion_rates": {
    "pre_screen_to_consent": 0.84,
    "consent_to_screen": 0.97,
    "screen_to_eligible": 0.69,
    "eligible_to_randomized": 0.93,
    "overall": 0.44
  },
  "screen_failure_reasons": {
    "inclusion_not_met": 45,
    "exclusion_met": 35,
    "withdrew_consent": 10,
    "lost_to_followup": 5
  }
}
```

---

## Format Export Examples

### Export to SDTM

```
Generate a Phase III trial and export as SDTM datasets
```

**Output includes:**
- DM (Demographics)
- AE (Adverse Events)
- CM (Concomitant Medications)
- DS (Disposition)
- EX (Exposure)
- LB (Laboratory)
- MH (Medical History)
- VS (Vital Signs)

### Export to ADaM

```
Generate analysis datasets for a survival trial
```

**Output includes:**
- ADSL (Subject-Level)
- ADAE (Adverse Event Analysis)
- ADTTE (Time-to-Event Analysis)
- ADLB (Laboratory Analysis)
- ADRS (Response Analysis)

---

## Quick Reference

### Trial Phase Requests

| Request | Skill Used | Key Features |
|---------|------------|--------------|
| "Phase I 3+3 design" | phase1-dose-escalation.md | DLT-based escalation, MTD |
| "Phase I BOIN design" | phase1-dose-escalation.md | Bayesian intervals |
| "Phase I CRM" | phase1-dose-escalation.md | Model-based dosing |
| "Phase II Simon's two-stage" | phase2-proof-of-concept.md | Futility stopping |
| "Phase II MCP-Mod" | phase2-proof-of-concept.md | Dose-response modeling |
| "Phase III superiority" | phase3-pivotal.md | Primary efficacy |
| "Phase III non-inferiority" | phase3-pivotal.md | NI margin testing |

### Therapeutic Area Triggers

| Say This | Get This |
|----------|----------|
| "oncology", "cancer", "tumor" | RECIST, tumor response, survival |
| "cardiovascular", "heart", "MACE" | CV outcomes, cardiac biomarkers |
| "CNS", "neuro", "Alzheimer's" | Cognitive scales, imaging |
| "gene therapy", "CAR-T", "CGT" | Long-term follow-up, CRS, ICANS |

### SDTM Domain Triggers

| Domain | Trigger Phrases |
|--------|-----------------|
| DM | "demographics", "subject characteristics" |
| AE | "adverse events", "safety", "TEAEs" |
| CM | "concomitant medications", "prior meds" |
| LB | "laboratory", "labs", "chemistry", "hematology" |
| VS | "vital signs", "blood pressure", "vitals" |
| EX | "exposure", "dosing", "treatment administered" |
| DS | "disposition", "discontinuation", "completion" |
| MH | "medical history", "comorbidities" |

---

## Tips for Best Results

1. **Specify the phase** - "Phase I 3+3" is more specific than just "dose escalation"

2. **Include design parameters** - "Simon's two-stage with p0=0.10, p1=0.30"

3. **Request specific domains** - "Generate DM and AE domains"

4. **Use therapeutic area context** - "Oncology Phase III" activates RECIST patterns

5. **Ask for specific formats** - "as SDTM" or "as ADaM" for regulatory output

6. **Combine requests** - "Phase III NSCLC trial with 200 subjects, AE and LB domains, as SDTM"

---

## Dimensional Analytics Examples

TrialSim supports generating data in star schema format for BI analytics, dashboards, and operational reporting.

### Example 1: Basic Dimensional Model for DuckDB

```
Generate a Phase III oncology trial with 100 subjects as star schema for DuckDB
```

**What you get:**
- `dim_study` - Study attributes (phase, indication, sponsor)
- `dim_site` - 10 sites with geography
- `dim_subject` - 100 subjects with demographics
- `dim_treatment_arm` - 2 arms (experimental + placebo)
- `fact_enrollment` - Enrollment milestones per subject
- `fact_adverse_event` - Treatment-emergent AEs
- `fact_efficacy` - RECIST tumor assessments

### Example 2: Safety Surveillance Analytics

```
Generate 200 subjects for Phase III cardiovascular trial with full safety data 
in dimensional format. Include AE rates by SOC.
```

**What you get:**
- Complete star schema with MedDRA dimension
- Safety fact tables with CTCAE grades
- Query-ready structure for:
  - AE incidence by treatment arm
  - SAE rates by System Organ Class
  - Time-to-first-AE analysis

**Sample Query Output:**
```sql
-- Generated by Claude for safety surveillance
SELECT
    a.arm_name,
    m.soc_term as system_organ_class,
    COUNT(*) as ae_count,
    SUM(CASE WHEN f.is_serious THEN 1 ELSE 0 END) as sae_count,
    SUM(CASE WHEN f.ctcae_grade >= 3 THEN 1 ELSE 0 END) as grade_3_plus
FROM fact_adverse_event f
JOIN dim_treatment_arm a ON f.arm_key = a.arm_key
JOIN dim_meddra m ON f.meddra_key = m.meddra_key
GROUP BY a.arm_name, m.soc_term
ORDER BY ae_count DESC;
```

### Example 3: Enrollment Operations Dashboard

```
Create a clinical trial operations dashboard dataset with enrollment velocity 
and site performance metrics. Load to DuckDB.
```

**What you get:**
- `fact_enrollment` with screening-to-randomization metrics
- `fact_visit` with protocol compliance metrics
- Site-level aggregations ready for dashboards:
  - Subjects screened/enrolled by site
  - Screen failure rates
  - Visit compliance percentages

### Example 4: Databricks Enterprise Loading

```
Generate Phase II CNS trial with 80 subjects and full dimensional model.
Load to Databricks catalog 'dev_catalog', schema 'analytics'
```

**Claude workflow:**
1. Confirms Databricks CLI authentication
2. Generates canonical trial data
3. Transforms to dimensional model
4. Creates tables via SQL Statements API
5. Loads data with INSERT statements
6. Reports success with row counts

### Example 5: Cross-Product Analytics Setup

```
Generate 50 trial subjects with PatientSim linkage for cross-product analytics.
Include patient_mrn for EMR correlation.
```

**What you get:**
- `dim_subject` with `patient_mrn` field populated
- Matching `dim_patient` entries in PatientSim schema
- Ready for cross-product queries:
  - Correlate baseline disease burden with trial response
  - Link EMR medical history with trial adverse events
  - Analyze prior therapies impact on efficacy

### Example 6: Complete Trial Analytics Package

```
Generate a complete Phase III NSCLC trial package for analytics:
- 300 subjects (200 treatment, 100 placebo)
- 25 sites across NA and EU
- 12-month follow-up
- Full safety, efficacy, and operations data
- Star schema for DuckDB

Then show me:
1. Enrollment velocity by site
2. AE rates by arm and SOC
3. ORR by treatment arm
```

**Complete workflow:**
1. Claude generates comprehensive trial data
2. Creates star schema tables in DuckDB
3. Runs the requested analytics queries
4. Presents results in formatted tables

---

## See Also

### Phase Skills
- [Phase 1 Dose Escalation](../../skills/trialsim/phase1-dose-escalation.md)
- [Phase 2 Proof-of-Concept](../../skills/trialsim/phase2-proof-of-concept.md)
- [Phase 3 Pivotal](../../skills/trialsim/phase3-pivotal.md)

### SDTM Domain Skills
- [Demographics (DM)](../../skills/trialsim/domains/demographics-dm.md)
- [Adverse Events (AE)](../../skills/trialsim/domains/adverse-events-ae.md)
- [Laboratory (LB)](../../skills/trialsim/domains/laboratory-lb.md)
- [Vital Signs (VS)](../../skills/trialsim/domains/vital-signs-vs.md)
- [Exposure (EX)](../../skills/trialsim/domains/exposure-ex.md)
- [Disposition (DS)](../../skills/trialsim/domains/disposition-ds.md)
- [Medical History (MH)](../../skills/trialsim/domains/medical-history-mh.md)
- [Concomitant Medications (CM)](../../skills/trialsim/domains/concomitant-meds-cm.md)

### Therapeutic Area Skills
- [Oncology](../../skills/trialsim/therapeutic-areas/oncology.md)
- [Cardiovascular](../../skills/trialsim/therapeutic-areas/cardiovascular.md)
- [CNS/Neurology](../../skills/trialsim/therapeutic-areas/cns.md)
- [Cell & Gene Therapy](../../skills/trialsim/therapeutic-areas/cgt.md)

### Format Skills
- [CDISC SDTM Format](../../formats/cdisc-sdtm.md)
- [CDISC ADaM Format](../../formats/cdisc-adam.md)
- [Dimensional Analytics](../../formats/dimensional-analytics.md)

### Reference Materials
- [TrialSim Canonical Models](../../references/data-models.md#trialsim-models)
